netFormulary Chelsea and Westminster Hospital NHS
NHS Foundation Trust  
 Search
 Results

Looking for Adalimumab found 40 matches

Formulary items 14 matches
   
Formulary BNF Category
  Abatacept  (Orencia®) Drugs affecting the immune response - 10.01.03
  Adalimumab  (Humira®)
(Dermatology)
Drugs affecting the immune response - 13.05.03
  Adalimumab  (Humira®)
(Gastroenterology)
Cytokine inhibitors - 01.05.03
  Adalimumab  (Humira® Amgevita®) Drugs affecting the immune response - 10.01.03
  Certolizumab Pegol  (Cimzia®) Drugs affecting the immune response - 10.01.03
  Etanercept  (Enbrel®)
(Dermatology)
Drugs affecting the immune response - 13.05.03
  Etanercept  (Enbrel®) Drugs affecting the immune response - 10.01.03
  Golimumab  (Simponi®) Drugs affecting the immune response - 10.01.03
  Golimumab  (Simponi®)
(Gastroenterology)
Cytokine inhibitors - 01.05.03
  Infliximab  (Remicade® Remsima®)
(Gastroenterology)
Cytokine inhibitors - 01.05.03
  Infliximab  (Remicade®)
(For use in line with NICE guidance)
Drugs affecting the immune response - 10.01.03
  Rituximab  (MabThera®) Drugs affecting the immune response - 10.01.03
  Tocilizumab  (RoActemra®) Drugs affecting the immune response - 10.01.03
  Ustekinumab  (Stelara®) Drugs affecting the immune response - 13.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in subsection NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
link in drug section NICE TA146: Psoriasis - adalimumab (13.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)


 

netFormulary